PREDICTING HUMAN TUMOR RESPONSE BY 31P MRS

通过 31P MRS 预测人类肿瘤反应

基本信息

批准号：
6650541
负责人：
Truman R Brown
金额：
$ 117.8万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
1995
资助国家：
美国
起止时间：
1995-05-18 至 2005-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6650541
关键词：
acidity /alkalinity breast neoplasms clinical trials cooperative study human subject human therapy evaluation hyperthermia therapy neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy neoplasm /cancer therapy nonHodgkin's lymphoma nuclear magnetic resonance spectroscopy prognosis sarcoma statistics /biometry

项目摘要

DESCRIPTION: This application is from the FCCC. The 31-phosphorus (31-P) nuclear magnetic resonance (NMR) spectroscopy (MRS) resonance of human cancers in vivo reveals metabolic characteristics which differ from those of normal tissues. These include elevations in PME, PDE, and of cellular pH, and dimininution of PCr. Published studies show that MRS- derived pH and MRI-derived T2 relaxation time predict response of soft tissue sarcomas to radiation and hyperthermia, and that changes in PME's predict response of several different human cancers to chemotherapy and radiation. The applicant proposes a prospective trial to test the hypotheses that in vivo 31-P MRS can predict sensitivity or resistance to treatment inpatients with types of cancers especially well suited to determine the clinical utility of MRS in cancer management, in particular non-Hodgkin's lymphomas and locally-advanced primary breast cancers. This will be done by correlating response rate and disease-free survival to metabolic features in the baseline spectrum and to changes in the spectrum occurring early following initiation of treatment. This application is the central one of 8 interactive R01 applications from institutions cooperating to study over 1500 patients with non-Hodgkin's lymphomas, locally-advanced breast cancers,sarcomas, and carcinomas of the head and neck. Attention will be paid to patient selection, protocol management, technical quality control and statistical analyses. The state-of-the-art techniques used will be uniform across the 8 institutions and will include: (1) The use of dual-tuned proton/phosphorus surface coils to interrogate various tumor anatomical locations. (2) Proton-decoupling of phosphorus spectra to distinguish individual components of phospholipid metabolites in the PME and PDE regions. (3) Image-guided 3-dimensional chemical shift imaging to accurately localize 13P NMR spectra to tumor masses, and (4) Molar quantitation of metabolite concentrations in the tumors. This application also proposes to establish standards for cooperative MRS trials in other diseases and clinical settings, and seeks to pave the way for clinical trials in which MRS could be used to intervene in the selection of treatment regimens in individual patients with cancer.

描述：此应用程序来自FCCC。 31磷（31-P）核磁共振（NMR）光谱（MRS）共振体内癌症揭示了代谢特征，这些特征与正常组织的。其中包括PME，PDE和细胞pH和PCR的减少。发表的研究表明，MRS- 派生的pH和MRI衍生的T2松弛时间可预测软的响应组织肉瘤到辐射和热疗，并且PME的变化预测几种不同的人类癌对化学疗法和辐射。申请人提出了一项前瞻性试验，以测试假设体内31-P MRS可以预测灵敏度或抗性治疗类型的癌症的住院患者，特别适合确定MRS在癌症管理中的临床实用性，特定的非霍奇金的淋巴瘤和局部精美的原发性乳房癌症。这将通过将反应率和无病生存率相关联基线光谱中的代谢特征和变化启动治疗后早期发生频谱。这应用程序是来自8个交互式R01应用程序中的中心合作研究1500多名非霍奇金患者的机构淋巴瘤，局部吸收的乳腺癌，肉瘤和癌头和脖子。注意患者选择，方案将注意管理，技术质量控制和统计分析。这使用的最新技术将在8个中均匀机构将包括：（1）使用双音调质子/磷表面线圈以询问各种肿瘤解剖学位置。（2）磷光谱的质子偶联以区分 PME和PDE中磷脂代谢产物的单个成分地区。（3）图像引导的3维化学移动成像准确地将13p NMR光谱定位到肿瘤肿块，（4）摩尔定量肿瘤中的代谢产物浓度。这申请还建议建立合作MRS的标准其他疾病和临床环境的试验，并试图铺平进行临床试验的方法，可以使用MRS干预在个别癌症患者中选择治疗方案。